CClinicalTrials.gg
CompletedNCT04462016Updated Jul 8, 2020

Effects of Calamansi on Blood Glucose

An interventional study of Calamansi and Glucose in Blood Glucose Response, sponsored by University Malaysia Sarawak. Completed at 1 site in Malaysia. Open to male participants aged 18 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-08.

Sponsored by University Malaysia Sarawak · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Feb 2018, registered Jul 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 21 Years
Sex
Male
01

Study summary

It is important to bring the blood glucose levels of those with type 2 diabetes mellitus (T2DM) back to normal levels as this can stop the condition from worsening and prevent other conditions that are related to T2DM from developing. One way to maintain healthy blood glucose level is the use of the glycaemic index (GI), which ranks food according to how the body responds to its carbohydrate content. Low GI foods corresponds to low increase in blood glucose levels. Calamansi is a citrus that is believed not to induce an increase in blood glucose levels. Since beverages from calamansi are available and diabetes is a health concern in the community, it is important to investigate the effect of consuming this drink. Finger prick blood were tested in order to obtain the blood glucose levels for calculating the GI for the calamansi drink.

02

Conditions studied

  • Blood Glucose Response

Keywords

  • calamansi
  • glycaemic index
  • post-prandial blood glucose
03

In context

Lead sponsor

University Malaysia Sarawak is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 21 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • non-smoker
  • BMI between 18.5 and 24.99 kg/m2
  • waist circumference less than 102 cm
  • random blood glucose less than 7.8 mmol/L
  • negative urine dipstick result
  • not on any medications
  • no family history of inherited diseases
  • no heart conditions (angina, arrhythmia or heart failure)
  • no history of acute medical or surgical event within the past 6 months.

Exclusion criteria

Exclusion Criteria:

  • pre-existing conditions such as HIV, hepatitis, inflammatory bowel diseases, diabetes mellitus, kidney disease, blood disorders (such as thalassaemia)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
10 participants (actual)

Study arms

  • Active comparator
    Reference drink

    Healthy volunteers' blood glucose response to reference drink (glucose)

    Other: Glucose

  • Experimental
    Test drink

    Healthy volunteers' blood glucose response to test drink (calamansi)

    Other: Calamansi

Interventions

  • OtherCalamansi

    250 ml of a commercially sourced calamansi drink

  • OtherGlucose

    75 g of glucose dissolved in 250 ml of drinking water

06

What researchers measure

Primary outcomes

  1. Change from baseline blood glucose levels

    Capillary blood glucose using glucometer

    Time frame: 30, 60, 90, 120 min after drinking

Secondary outcomes

  1. Change from baseline urinary glucose levels

    Dipstick test

    Time frame: 30, 60, 90, 120 min after drinking

07

Study locations

1 site
  • Faculty of Medicine and Health Sciences
    Kuching, Sarawak 94300, Malaysia
08

References and documents

Publications

  • Siner A, Sevanesan MS, Ambomai T, Abd Wahab Z, Lasem L. Blood glucose response to a calamansi drink in healthy adults: a non-randomised study. BMC Res Notes. 2020 Aug 28;13(1):404. doi: 10.1186/s13104-020-05250-8. PubMed 32859257 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04462016
Lead sponsor
University Malaysia Sarawak
Responsible party
Sponsor
First posted
Jul 8, 2020
Start date
Feb 2, 2018
Primary completion
May 6, 2018
Completion
Aug 8, 2018
Last update
Jul 8, 2020

Study contacts

Angela Siner, PhD
principal investigator · Universiti Malaysia Sarawak

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion